<DOC>
	<DOCNO>NCT01157182</DOCNO>
	<brief_summary>The objective study determine compare rate extent absorption norethindrone unconjugated estradiol test formulation Estradiol/Norethindrone Acetate Tablets , 1 mg/0.5 mg versus reference Activella® ( 1 mg estradiol/0.5 mg norethindrone acetate ) Tablets fasting condition .</brief_summary>
	<brief_title>Estradiol/Norethindrone Acetate Tablets , 1/0.5 mg Under Fasting Conditions</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA Bioequivalence Statistical Methods</detailed_description>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Nonsmoking smoking ( 10 cigarettes/day ) , physiologically surgically postmenopausal female within age range 1865 year . 17βestradiol serum level &lt; 90 pmol/L folliclestimulating hormone ( FSH ) &gt; 40 IU/L . Body Mass Index great equal 19.0 less equal 32.0 . Normal finding physical examination , 12lead electrocardiogram ( ECG ) vital sign . Hemoglobin &gt; 115 g/L Normal Pap smear within 6 month . Normal mammogram within 1 year subject age 50 year . Negative drug abuse alcohol . Negative hepatitis B surface antigen , hepatitis C Human Immunodeficiency Virus ( HIV ) . No clinical laboratory value outside acceptable range define BCR , unless Principal Investigator Subinvestigator decide clinically significant . Negative pregnancy . Subjects surgically postmenopausal intact uterus ( i.e . bilateral oophorectomy ) least 6 month , physiologically postmenopausal ( i.e . spontaneous amenorrhea ) least 1 year , adhere contraceptive requirement least 10 day Period I check , study 1 month end study . Availability subject entire study period willingness subject adhere protocol requirement , evidence sign ICF . Known history hypersensitivity norethindrone estradiol combination and/or norethindrone , and/or estradiol . Known history presence cardiac , pulmonary , gastrointestinal , endocrine , musculoskeletal , neurological , hematological disease , malignancy , migraine , unless deem NCS Principal Investigator Subinvestigator . Known history liver , kidney , and/or gallbladder dysfunction/disease , chronic diarrhea inflammatory bowel disease . Known history presence cerebrovascular diseases venous thromboembolic event , include deep vein thrombosis , pulmonary embolism , retinal vein thrombosis . Any history stroke . Presence significant physical organ abnormality . History osteoporosis . History presence fibrocystic breast disease . History presence breast , endometrial , cervical , and/or uterine carcinoma . Any illness 4 week study , unless deem NCS Principal Investigator Subinvestigator . Any history evidence psychiatric psychological disease , unless deem NCS Principal Investigator Subinvestigator . Any history abnormal vaginal bleeding , unless deem NCS Principal Investigator Subinvestigator . Any history asthma ( 12 year age ) . Evidence pregnancy lactation . Any history severe allergic reaction ( include drug , food , insect bite , environmental allergen ) . Known history presence food allergy , condition know interfere absorption , distribution , metabolism , excretion drug . Any history drug abuse . Any recent history alcohol abuse ( less 1 year ) . Use prescription medication within 30 day precede study . Use hormone replacement therapy within 30 day drug administration . Use overthecounter medication herbal supplement within 7 day precede study ( except spermicidal/barrier contraceptive product ) . Use hormonal contraceptive within 30 day drug administration depot injection progestogen drug within 1 year drug administration . Depot injection drug ( progestogen ) within 6 month . Blood draw within 56 day precede study , conduct clinical study facility BCR , within lockout period specify previous study conduct BCR . Blood donation within 56 day precede study . Participation plasma donor plasmapheresis program within 7 day precede study . Participation clinical trial investigational drug within 30 day precede study . Intolerance venipuncture .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Post-Menopausal</keyword>
</DOC>